Rašić Ismar, Rašić Azra, Akšamija Goran, Radović Svjetlana, Šehović Nedžad
Clinic for General and Abdominal Surgery, Sarajevo, Bosnia and Herzegovina.
Clinic for Oncology; Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Med Glas (Zenica). 2017 Aug 1;14(2):229-235. doi: 10.17392/908-17.
Aim To determine the serum levels of matrix metalloproteinase 9 (MMP-9) concentration and their association with the stage and histopathologic sizes of colorectal cancer (CRC). Methods One hundred and two patients with clinically diagnosed and histologically confirmed colorectal cancer ready for surgical treatment were included in the study. In each patient, preoperative peripheral venous blood samples were taken for determination of the concentration of MMP-9 using ELISA immunoassay test. Resected tumour specimens were studied pathologically according to the criteria of the TNM classification. All patients were divided into groups according to the TNM classification. The control group presented 30 subjects of the appropriate age and gender with no family history of cancer, clinical signs of malignancy or inflammatory bowel disease. Results The serum levels of MMP-9 were progressively increased in patients with CRC reaching the highest value in the fourth stage of CRC. It was also confirmed that the serum concentrations of MMP-9 were significantly higher in patients with pericolonic lymph nodes involvement compared to the patients with no involvement of lymph nodes, 456.4 (445.9-464.7) ng/mL vs. 438.4 (418.4-447.8) ng/mL (p<0.001). Significantly higher serum levels of MMP-9 were found in the patients with metastatic CRC, 458.5 (452.0-468.1) ng/mL compared with the CRC patients without metastasis, 445.8 (436.9-456.5) ng/mL (p<0.001). Conclusion It was confirmed that serum concentration of MMP-9 presented the significant independent risk factors for the progression of CRC.
目的 测定基质金属蛋白酶9（MMP - 9）的血清浓度及其与结直肠癌（CRC）分期和组织病理学大小的关系。方法 本研究纳入102例临床诊断且经组织学证实、准备接受手术治疗的结直肠癌患者。每位患者术前采集外周静脉血样本，采用酶联免疫吸附测定法（ELISA）检测MMP - 9浓度。切除的肿瘤标本按照TNM分类标准进行病理研究。所有患者根据TNM分类分组。对照组为30名年龄和性别合适、无癌症家族史、无恶性临床体征或炎症性肠病的受试者。结果 CRC患者血清MMP - 9水平逐渐升高，在CRC第四阶段达到最高值。还证实，与无结肠旁淋巴结受累的患者相比，有结肠旁淋巴结受累患者的血清MMP - 9浓度显著更高，分别为456.4（445.9 - 464.7）ng/mL和438.4（418.4 - 447.8）ng/mL（p<0.001）。转移性CRC患者的血清MMP - 9水平显著高于无转移的CRC患者，分别为458.5（452.0 - 468.1）ng/mL和445.8（436.9 - 456.5）ng/mL（p<0.001）。结论 证实血清MMP - 9浓度是CRC进展的重要独立危险因素。
